New hope for myeloma relapse: Two-Drug combo aims to outperform standard care
NCT ID NCT07463807
First seen Mar 21, 2026 · Last updated May 01, 2026 · Updated 6 times
Summary
This study compares a new two-drug combination (teclistamab and pomalidomide) to a standard three-drug regimen for adults whose multiple myeloma has returned after initial treatment. The goal is to see if the new combo is safer and better at wiping out cancer cells to undetectable levels. About 162 participants will be enrolled, and the study is not yet recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.